Home Cart Sign in  
Chemical Structure| 2416131-46-7 Chemical Structure| 2416131-46-7

Structure of NX-2127
CAS No.: 2416131-46-7

Chemical Structure| 2416131-46-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NX-2127 is a selective BTK inhibitor that can specifically induce the degradation of the mutant BTKC481S. It has important application prospects in T cell activation and immune regulation research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NX-2127

CAS No. :2416131-46-7
Formula : C39H45N9O5
M.W : 719.83
SMILES Code : O=C(C1=NC=C(N2CCCCC2)N=C1NC3=CC=C(C4CCN(C[C@H]5CN(C6=CC7=C(C(N(C(CC8)C(NC8=O)=O)C7=O)=O)C=C6)CC5)CC4)C=C3)N
MDL No. :MFCD34789579

Safety of NX-2127

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of NX-2127

RTK

Isoform Comparison

Biological Activity

Description
NX-2127 is characterized as a potent oral BTK inhibitor that facilitates the degradation of the BTKC481S mutation in cells and is more effective than Ibrutinib in halting the proliferation of BTKC481S mutant TMD8 cells. It also promotes the breakdown of Ikaros (IKZF1) and Aiolos (IKZF3), with IC50 values of 25 nM and 54 nM, respectively. Furthermore, NX-2127 activates T cells and elevates IL-2 production in primary human T cells[1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04830137 Chronic Lymphocytic Leukemia (... More >>CLL)|Small Lymphocytic Lymphoma (SLL)|Waldenstrom Macroglobulinemia (WM)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)|Follicular Lymphoma (FL)|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Central Nervous System Lymphoma (PCNSL) Less << PHASE1 RECRUITING 2025-12-26 City of Hope, Duarte, Californ... More >>ia, 91010, United States|University of California Irvine, Orange, California, 92868, United States|University of California San Francisco Medical Center, San Francisco, California, 94143, United States|Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, 34203, United States|The University of Chicago Medical Center, Chicago, Illinois, 60637, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20814, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45267, United States|OSU Wexner Medical Center, Columbus, Ohio, 43210, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Baylor University Medical Center, Dallas, Texas, 75246, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, 84112, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.95mL

1.39mL

0.69mL

13.89mL

2.78mL

1.39mL

References

 

Historical Records

Categories